ERBB2 and triple-negative breast carcinoma: In the KEYNOTE-522 (40) and IMpassion130 (41) trials, chemotherapy combined with immunotherapy resulted in significantly higher pCR rates in patients with triple-negative breast cancer, while the effect was more limited in HR+/HER2- patients.